x - chloramphenicol palmitate powder
ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) - chloramphenicol palmitate 24750 g in 25000 g
x- chloramphenicol palmitate powder
ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) - chloramphenicol palmitate .99 kg in 1 kg
chloramphenicol palmitate powder
darmerica, llc - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -
chloramphenicol palmitate powder
bluebay shandong co.,ltd - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -
chloramphenicol palmitate powder
bluebay shandong co.,ltd - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -
chloramphenicol palmitate powder
wang pharmaceuticals & chemicals - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -
chloramphenicol palmitate powder
ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -
chloramphenicol palmitate powder
darmerica, llc - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) -
chloramphenicol palmitate 125mg/5ml oral liquid ordinary suspensions
abacus pharma (a) ltd. - chloramphenicol palmitate - oral liquid ordinary suspensions - 125mg/5ml
chloramphenicol sodium succinate- chloramphenicol sodium succinate injection, powder, lyophilized, for solution
fresenius kabi usa, llc - chloramphenicol sodium succinate (unii: 872109hx6b) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 1 g in 10 ml - in accord with the concepts in the warning box and this indications and usage section, chloramphenicol must be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. however, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. the decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional conce